CTMX vs NVS
CytomX Therapeutics Inc (CTMX) versus NVS (NVS) — a side-by-side from cached financials, not a winner call.
CytomX Therapeutics Inc (CTMX) is a biotechnology company listed on US.
NVS (NVS) common stock.
Latest reported CTMX revenue for 2024-12-31 was $138.1M. Net income was $31.9M. Revenue was up 36.4% from 2023-12-31 to 2024-12-31. CTMX currently screens at market cap $653.1M.
NVS does not have a complete income-statement cache yet.
CTMX currently screens at market cap $653.1M. NVS currently screens at market cap $0.
Not investment advice. Open the CTMX and NVS stock pages for the full models.
Not investment advice.